Alkynyl Derivatives as DPP-1 Inhibitors for COPD and Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of Dipeptidyl Peptidase-1 (DPP-1) to treat conditions such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, and other disorders mediated by DPP-1, as current treatments are inadequate in addressing the inflammatory and proteolytic imbalances associated with these conditions.
Innovation Solution
Development of novel alkynyl derivatives that act as inhibitors of DPP-1, specifically compounds of formula (I) with specific ring structures and substituents, which are used in pharmaceutical compositions to treat DPP-1 mediated disorders, including COPD, asthma, and rheumatoid arthritis, by inhibiting the activity of DPP-1 and thereby reducing proteolytic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for DPP-1 mediated disorders, then treatment is provided, but the treatments are inadequate in addressing the inflammatory and proteolytic imbalances
Solution Approach 1:
The patent develops novel alkynyl derivatives with specific molecular structures (formula I) that change the pharmacological parameters of DPP-1 inhibition. These compounds achieve potent and selective inhibition of DPP-1 catalytic activity, addressing the inadequacies of current treatments by providing a new chemical entity with optimized inhibitory properties against the target enzyme.
2Reliability
If a drug inhibits all or most of the relevant proteases, then effectiveness in treating COPD is expected to improve, but the complexity of the drug molecule increases
Solution Approach 1:
The alkynyl derivatives of formula (I) act as universal inhibitors against multiple proteases including neutrophil elastase, cathepsin G, proteinase 3, granzymes A and B, and DPP-1. A single molecule structure achieves broad-spectrum inhibition through its design features: the P1' alkynyl group and P2 dipeptide moiety enable simultaneous binding to multiple protease active sites, providing multi-functionality without requiring multiple separate drugs.
Solution Approach 2:
The drug molecule combines multiple functional groups into a composite structure: the P1' alkynyl derivative portion (with specific ring structures A and substituents) combined with the P2 dipeptide portion (amino acid residues). This composite molecular architecture enables the single compound to interact with multiple protease targets simultaneously, achieving broad inhibition through structural integration rather than molecular complexity.
Data Source
AI summary
The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.